Jean-Paul Behr has spent most of his career at the University of Strasbourg. After a doctorate in physical organic chemistry under the supervision of Jean-Marie Lehn (1973) followed by a postdoctoral internship in England, he founded the Genetic Chemistry Laboratory at the Faculty of Pharmacy in Strasbourg. His research there focused mainly on the development of molecules capable of encapsulating DNA and transporting it inside living cells. Jean-Paul Behr developed the first effective lipid vectors,[2][3] then polymeric,[4] which were marketed under the names TransfectamTM, LipofectamineTM and jetPEITM. These vectors are widely used as transfection agents for animal cells in culture, but also as drug-gene carriers in clinical gene therapy trials. To this end, he founded two biotechnology companies, Eurothéra[5] (1994–97) and Polyplus-transfection[6] (2001).
^Behr, J.P., « DNA strongly binds to micelles and vesicles containing lipopolyamines or lipointercalants », Tetrahedron Lett, 1986. 27, p. 5861-5864
^Behr, J.P., « Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine- coated DNA », Proc Natl Acad Sci U S A, 1989. 86 (18), p. 6982-6986
^Boussif, O, « A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine », Proc Natl Acad Sci U S A,, 1995. 92 (16), p. 7297-7301
Biography of the Academy of Sciences. http://www.academie-sciences.fr/fr/Liste-des-membres-de-l-Academie-des-sciences-/-B/jean-paul-behr.html
Towards artificial viruses. https://www.lemonde.fr/savoirs-et-connaissances/article/2002/10/21/jean-paul-behr-vers-des-virus-artificiels_295032_3328.html
The drug revolution of the future. http://sante.lefigaro.fr/actualite/2012/03/16/17774-revolution-medicaments-futur